AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Drug Development

ICYMI: A Closer Look at News You Might Have Missed This Week

The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.

March 18, 2021

7 min read

Heather McKenzie

BioMidwest

AbbVie Could Sell Off $5 Billion Portfolio of Women’s Drugs

One year after AbbVie’s $63 billion purchase of Allergan, the company is reportedly lining up the sale of a portfolio of women’s drugs and health care products valued at $5 billion.

March 16, 2021

2 min read

Alex Keown

BioMidwest

AbbVie to Fund Mitokinin’s Parkinson Research with Option to Buy

AbbVie bought an exclusive right to acquire San Francisco-based Mitokinin after the company completes its Investigational New Drug-enabling studies on its lead program, PINK1, for Parkinson’s disease.

March 2, 2021

2 min read

Mark Terry

Deals

Beijing CRMO Further Expands UK Footprint with Abbvie’s Allergan Site

Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.

March 1, 2021

2 min read

Kate Goodwin

AbbVie_© AbbVie Inc. All rights reserved.

FDA

Humira Bags Another FDA Approval, This Time for Pediatric Ulcerative Colitis

The U.S. Food and Drug Administration has approved AbbVie’s biologic therapy HUMIRA® (adalimumab) as a treatment for moderate-to-severe active ulcerative colitis in children aged 5 years and older.

February 25, 2021

2 min read

Brandon May

Courtesy of Smith Collection/Gado/Getty Images

Policy

AbbVie Settles Botox Rival IP Lawsuit with Evolus

AbbVie and its partner company, Medytox of South Korea, have settled a years-long intellectual property legal dispute with California’s Evolus over Jeuveau, a potential rival to AbbVie’s blockbuster Botox, which it gained through the acquisition of Allergan.

February 19, 2021

2 min read

Alex Keown

Business

AbbVie, Caribou Biosciences Collaborate in $40 Million CAR-T Cell Deal

AbbVie committed up to another $300 in potential milestone payments.

February 10, 2021

2 min read

Mark Zipkin

Business

An Early February Focus on U.S.-Asia Drug Development Deals - UPDATED

Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a look at three of them.

February 2, 2021

6 min read

Heather McKenzie

Drug Development

JPM2021, Day 2: Gilead, Merck, AbbVie, Pfizer and More

As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.

January 13, 2021

5 min read

Mark Terry

JOBS